Table 3.
Relative Risk of Death in Zoledronic Acid–Treated Subjects Compared With Placebo‐Treated Subjects by Subgroup
| Subgroup | Cumulative death rates, zoledronic acid, N = 1054 (%) | Cumulative death rates, placebo, N = 1057 (%) | Hazard ratio (95% CI) |
|---|---|---|---|
| Gender | |||
| Male | 32/244 (22.0) | 51/261 (25.5) | 0.71 (0.46, 1.31) |
| Female | 69/810 (11.9) | 90/796 (15.6) | 0.74 (0.54, 1.02) |
| Race | |||
| Caucasian | 93/962 (14.6) | 128/960 (18.2) | 0.73 (0.56, 0.95) |
| Other | 8/92 (10.2) | 13/97 (16.7) | 0.63 (0.26, 1.51) |
| Age | |||
| <75 years | 23/477 (5.1) | 31/460 (9.8) | 0.75 (0.44, 1.28) |
| 75–84 years | 44/440 (16.7) | 64/447 (20.4) | 0.71 (0.49, 1.05) |
| ≥85 years | 34/137 (31.7) | 46/150 (36.7) | 0.72 (0.46, 1.12) |
| Region | |||
| North America | 54/297 (22.0) | 74/313 (25.4) | 0.76 (0.53, 1.07) |
| Latin America | 9/132 (7.8) | 17/131 (20.2) | 0.54 (0.24, 1.21) |
| Western Europe | 23/356 (9.9) | 32/353 (13.4) | 0.71 (0.42, 1.21) |
| Eastern Europe | 15/269 (6.3) | 18/260 (8.4) | 0.81 (0.41, 1.61) |
| BMI (kg/m2) | |||
| <19 | 11/79 (19.0) | 23/72 (42.8) | 0.43 (0.21, 0.89) |
| 19–25 | 54/502 (17.2) | 66/506 (15.7) | 0.82 (0.58, 1.18) |
| >25 | 28/441 (6.6) | 47/450 (17.4) | 0.59 (0.37, 0.95) |
| SPMSQ score | |||
| 0 | 24/524 (5.7) | 37/523 (10.8) | 0.65 (0.39, 1.09) |
| >0–2 | 25/283 (13.4) | 49/285 (24.8) | 0.47 (0.29, 0.77) |
| >2 | 40/168 (35.1) | 47/180 (31.6) | 0.96 (0.63, 1.46) |
| Femoral neck T‐score−2.5 or less | |||
| Greater than −2.5 to −1.5 | 52/448 (16.3) | 76/437 (22.6) | 0.70 (0.49, 0.99) |
| or less | 19/360 (9.4) | 28/374 (9.9) | 0.71 (0.40, 1.27) |
| Greater than −1.5 | 3/122 (4.1) | 12/121 (13.5) | 0.22 (0.06, 0.77) |
| Residence prior to hip fracture | |||
| Private home | 73/945 (11.9) | 103/928 (14.9) | 0.70 (0.52, 0.95) |
| Assisted living | 11/60 (25.6) | 17/61 (41.0) | 0.71 (0.33, 1.51) |
| Skilled nursing facility | 14/31 (55.6) | 18/44 (51.0) | 1.02 (0.51, 2.05) |